PUBLIC COMPANY
save$ALNYALNYLAM PHARMACEUTICALS, INC.
$ALNY219.72-4.96%Cambridge, MA, USupdated 20h ago
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
community read0 votes
pipeline
6
marketed
4
phase 3
2
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(6)
pipeline depth6 products
2Phase 34Marketed
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- phase1A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
- phase2A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
- phase3TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- phase2A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
- phase1A Study to Evaluate ALN-4915 in Adult Healthy Volunteers
- —ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
- —BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
🐶 Hiring Signal
next earnings Oct 29, 2026
News
- ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’Rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do, Ai3Bio’s therapies are designed to eliminate a particular group of T helper cells.biopharma_dive · 4d ago
- ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plansADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech City Therapeutics also plans a public listing.fiercebiotech · 9d ago
- ‘Worse than expected’ Wainua data muddies water for TTR silencersAstraZeneca and Ionis Pharmaceuticals’ data drop divulging more details from its highly watched Phase 3 transthyretin silencer trial “further confuses the picture” for Wainua when combined with the…biospace · 1mo ago
- STAT+: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugsAstraZeneca detailed the surprise failure of a closely watched heart disease trial, a study with ripple effects for a competitive billion-dollar market.stat · 1mo ago
- STAT+: Alnylam’s heart drug troubles take center stage at a cardiology conferenceThe European Society of Cardiology Congress that kicks off Friday in Munich will be a consequential meeting for Alnylam Pharmaceuticals.stat · 1mo ago
- After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’With the post-IPO quiet period having come to an end, CEO Benny Sørensen, M.D., Ph.D., was free to sit down with Fierce to map out Hemab’s future.fiercebiotech · 1mo ago
- Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchiseAlnylam’s revenue cut “may create a near term credibility overhang and could “raise questions on peak sales potential, even if there’s tailwinds in the competitive landscape,” according to Stifel.biospace · 2mo ago
- AstraZeneca, Ionis drug fails big heart disease study in major setbackEplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.biopharma_dive · 2mo ago
- Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.biopharma_dive · 5mo ago
Data sources
last refreshed 4m ago
Found something off?
comments(0)
5-min edit window · permanent after that